Posts Archive

NCT04770402: Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients

NCT04934475: Phase 3 - IFM 2020-02 Minimal Residual Disease Adapted Strategy (MIDAS) KRD-Isatuximab

NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma

THE MMRF - Multiple Myeloma Immunotherapy

NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)

What are the different stages of Multiple Myeloma? REVISED - INTERNATIONAL STAGING SYSTEM (R-ISS)

NCI National Cancer Institute: Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research

Multiple Myeloma Research Foundation - MMRF - Genomics

NCT04751877: Phase 3 - Isa-Rd +/- Bortezomib Non Frail NTE Myeloma Elderly Patients IFM2020-05

Patient Symposium - MCRT Webcast Myeloma Crowd Round Table, 05/08/2021, Dana-Farber Cancer Institute

NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)

NCT04843579: Phase 2: Selinexor in Combination With Clarithromycin, Pom & Dex RRMM - ClaSPd

NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma

Multiple Myeloma Research Foundation - MMRF - Clinical Trials

NCT04937777: EMN 23 - Study on the Management & Outcome of Systemic AL Amyloidosis in Europe

What is the MMRF CureCloud®? Welcome to the MMRF CureCloud! Multiple Myeloma Research Foundation

American Cancer Society - www.cancer.org: What is CART Cell Therapy?

NCT04935580: Phase 1/2: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Patient Symposium - MCRT Webcast Myeloma Crowd Round Table, 04/24/2021